Nordic Nanovector's Betalutin, or Lu-177 lilotomab satetraxetan, was granted fast-track status by the FDA as a treatment for adult patients with relapsed or refractory marginal zone lymphoma who have undergone two or more systemic therapies.
Marginal zone lymphoma drug gets FDA fast-track tag
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.